資源描述：
《中晚期巨塊型原發(fā)性肝癌的介入熱化療栓塞治療-論文.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、局解手術(shù)學(xué)雜志2013年第22卷第6期JREGANATOPERSURG，2013，Vol_22，N0．6中晚期巨塊型原發(fā)性肝癌的介入熱化療栓塞治療羅舒，陳非，郭黔(遂寧市第一人民醫(yī)院腫瘤科，四川遂寧629000)[摘要]目的探討介入熱化療栓塞(IHC)治療巨塊型原發(fā)性肝癌的療效，并與經(jīng)肝動(dòng)脈化療栓塞(TACE)進(jìn)行對(duì)比。方法IHC治療的中晚期巨塊型原發(fā)性肝癌患者68例作為觀察組，同期單純行TACE治療32例患者作為對(duì)照組。比較2組患者的療效、生存質(zhì)量、二次手術(shù)率、血清AFP下降程度、生存率及毒副作用。結(jié)果觀察組有效率(79．4％)顯著高于對(duì)照組(5
2、6．3％)，P<0．05。觀察組經(jīng)治療后二次手術(shù)切除率(70．6％)顯著高于對(duì)照組(43．8％)，P<0．01。觀察組經(jīng)治療后Karnofsky評(píng)分增加20分以上者(35．3％)顯著高于對(duì)照組(12．5％)，P<0．01；AFP下降程度大于50％者所占比例(52．9％)顯著高于對(duì)照組(25．0％)，P<0．01。觀察組術(shù)后12、18、24個(gè)月患者存活率均分別顯著高于對(duì)照組(P<0．01)。結(jié)論IHC治療巨塊型原發(fā)性肝癌療效顯著，可增加患者二次手術(shù)的機(jī)會(huì)，是治療巨塊型肝癌安全有效的治療方式之一。[關(guān)鍵詞]原發(fā)性肝癌；巨塊型；介入熱化療栓塞；經(jīng)肝動(dòng)脈化
3、療栓塞；療效[中圖分類(lèi)號(hào)]R735．7；R730．5[文獻(xiàn)標(biāo)識(shí)碼]A[文章編號(hào)]1672-5042(2013)06-0611-02InterventionalheatedchemotherapyformoderateandadvancedhugeprimaryhepatocellularcarcinomaLUOShu，CHENFei，GUOQian(DepartmentofOncology，F(xiàn)irstPeople’sHospitalofSuiningCity，SuiningSichuan629000，China)Abstract：0bjective
4、Toexploretheeffectsofthetherapeuticeffectsofinterventionalheatedchemotherapy(IHC)formoderateandadvancedhugeprimaryhepatocellularcarcinomaandcomparewithtranscatheterarterialchemoembolization(TACE)．MethodsThe68pa—tientswithmoderateandadvancedhugeprimaryhepatocellularcarcinomaacc
5、eptedthetreatmentofIHCwereconsideredastheobservationgroup，and32patientsmanagedTACEwereregardedasthecontrolgroup．Thetherapeuticeffects，livingquality，secondarysurgeryrates，ThereducedlevelofserumAFP，survivalrate，andtoxicsideeffectsof2groupswerecontrasted．ResultsTheeffectiverateof
6、observationgroupwasobviouslyhigherthanthatofcontrolgroup(79．4％vs56．3％，P<0．05)，andsecondarysurgeryrateswasincreased(70．6％vs43．8％，P<0．01)．TheratioofincreasedKarnofskyscorewasmorethan20inobservationgroup，whichwasobviouslyhigherthanthatofcontrolgroup(35．3％vs12．5％，P<0．01)．TThereduc
7、edlevelofserumAFPwasmorethan50％inobservationgroup，whichwashigherthanthatofcontrolgroup(52．9％vs25．0％，P<0．01)．Thesurvivalrateof12，18，24monthsaftertreatmentincontrolgroupwasin—creasedthanthatincontrolgroupindividually(P<0．01)．ConclusionIHCiseffectiveforhugeprimaryhepatocellularca
8、rcinomaandin—creasesthesecondarysurgeryrates，whichisoneofthes
